Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21454332 | 0.88 | CNR2 (0.36) | CNR2HSP90AA1PTPN1 | |
| SCHEMBL21254126 | 0.82 | ACHE (0.41) | MAPTPDE4DSMN1; SMN2HSP90AA1PTPN1 | |
| SCHEMBL21454562 | 0.81 | PTPN1 (0.41) | PTPN1 | |
| SCHEMBL21447064 | 0.80 | PTPN1 (0.44) | MALT1GRM2HSP90AA1PTPN1 | |
| SCHEMBL21454602 | 0.79 | MALT1 (0.37) | MALT1MAPTPLCG2CNR2GRM2 | |
| SCHEMBL21436843 | 0.76 | PTPN1 (0.32) | PTPN1 | |
| SCHEMBL22965202 | 0.75 | PTPN1 (0.37) | MALT1MAPTPLCG2CNR2HSP90AA1 | |
| SCHEMBL21254262 | 0.74 | TYR (0.38) | MAPTCNR2KMT2ASMN1; SMN2HSP90AA1 | |
| SCHEMBL21447037 | 0.73 | HSP90AA1 (0.40) | PDE4DHSP90AA1PTPN1 | |
| SCHEMBL21447076 | 0.72 | PTPN1 (0.41) | PDE4DGRM2HSP90AA1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3782999-B1 | METHOD FOR SYNTHESIZING 3-PHENYL-2,8-DIHYDROPYRANO [2,3-F] CHROMENE DERIVATIVE | GLACEUM INC (KR) | 2023-05-10 | — | — | EP | disclosed |
| EP-3782999-A1 | METHOD FOR SYNTHESIZING 3-PHENYL-2,8-DIHYDROPYRANO [2,3-F] CHROMENE DERIVATIVE | Glaceum, Inc. (KR) | 2021-02-24 | — | — | EP | disclosed |
| US-20210040106-A1 | METHOD FOR SYNTHESIZING 3-PHENYL-2,8-DIHYDROPYRANO [2,3-F] CHROMENE DERIVATIVE | Glaceum Inc. (KR) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040106-A1 | METHOD FOR SYNTHESIZING 3-PHENYL-2,8-DIHYDROPYRANO [2,3-F] CHROMENE DERIVATIVE | HPD, CYP2J2, PAH | MALT1 3699/4885MAPT 3047/4885PLCG2 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.